The 12th International AIDS Society Conference on HIV Science (IAS 2023)

Brisbane, Australia 23 July 2023 - 26 July 2023

The Geneva patient: Another score on the HIV remission board

01 Sep 2023 by

Another HIV patient may be on the way to a cure following stem cell therapy using wild-type (WT) CCR5 donor cells for a rare and aggressive blood cancer.

The Geneva patient: Another score on the HIV remission board

01 Sep 2023

Statin cuts CV risk in patients with HIV

31 Aug 2023 by

Treatment with pitavastatin is associated with a significantly lower risk of cardiovascular (CV) events in people living with human immunodeficiency virus (HIV) as shown in the final analysis of the double-blind, placebo-controlled REPRIEVE trial presented at IAS 2023.

Statin cuts CV risk in patients with HIV

31 Aug 2023

SNA a feasible HIV testing approach

28 Aug 2023 by

Social network testing approaches (SNA) for HIV testing may be an effective and acceptable approach to improve HIV testing in all populations, a systematic review and meta-analysis suggests.

SNA a feasible HIV testing approach

28 Aug 2023

Switching antiretroviral regimens does not help with weight loss

18 Aug 2023 by

Switching from an integrase inhibitor (INI)-based antiretroviral treatment (ART) regimen to a protease inhibitor (PI)-based regimen falls short of reversing weight gain while on the INI-based regimen, according to the results of the open-label phase IV DEFINE trial.

Switching antiretroviral regimens does not help with weight loss

18 Aug 2023

Circumcision may reduce HIV risk in men who have sex with men

17 Aug 2023 by

Voluntary medical male circumcision (VMMC) appears to cut the risk of contracting HIV infection among men who have sex with men (MSM), particularly those who mainly practice insertive anal sex, as shown in a study from China presented at IAS 2023.

Circumcision may reduce HIV risk in men who have sex with men

17 Aug 2023

Demedicalized delivery of PrEP possible, improves access

16 Aug 2023 by

A peer-led demedicalized delivery of same-day HIV pre-exposure prophylaxis (PrEP) in various community centres is feasible, suggests a Philippines study presented at the recent IAS 2023.

Demedicalized delivery of PrEP possible, improves access

16 Aug 2023

Meeting gender-affirming needs tied to accessing HIV services among transgender people

16 Aug 2023 by

Having met gender-affirming care needs among transgender people is associated with accessing HIV-related services in a community-led clinic, as shown in a Philippines study presented at IAS 2023.

Meeting gender-affirming needs tied to accessing HIV services among transgender people

16 Aug 2023

Risk of hypertension higher with DTG in PLWH

15 Aug 2023 by

In the secondary analysis of the NAMSAL and ADVANCE trials, first-line treatment with dolutegravir (DTG) was associated with significantly higher risks of treatment-emergent hypertension in people living with HIV (PLWH), especially in combination with tenofovir alafenamide (TAF).

Risk of hypertension higher with DTG in PLWH

15 Aug 2023

Tenofovir-containing regimen sustains high viral suppression in HIV-1/HBV coinfection

09 Aug 2023 by

Treatment with either bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG + F/TDF) resulted in similarly high and sustained rates of viral suppression in adults with HIV-1* and HBV** coinfection, according to a prespecified secondary analysis of the ALLIANCE trial presented at IAS 2023.

Tenofovir-containing regimen sustains high viral suppression in HIV-1/HBV coinfection

09 Aug 2023

Two-drug HIV regimen as good as B/F/TAF

08 Aug 2023 by

Among treatment-naïve patients with HIV-1* infection, initial treatment combination with doravirine and islatravir (DOR/ISL) was noninferior in achieving virologic suppression (HIV-1 RNA <50 copies/mL) at week 48 compared with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), according to a trial presented at IAS 2023.

Two-drug HIV regimen as good as B/F/TAF

08 Aug 2023